The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window.
about
Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspironeA delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learningFound in translation: Understanding the biology and behavior of experimental traumatic brain injuryCombination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?Environmental enrichment promotes robust functional and histological benefits in female rats after controlled cortical impact injuryA combined therapeutic regimen of buspirone and environmental enrichment is more efficacious than either alone in enhancing spatial learning in brain-injured pediatric ratsOld dog, new tricks: the attentional set-shifting test as a novel cognitive behavioral task after controlled cortical impact injury.Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesisEvaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury.Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT1A receptor agonist buspirone after experimental traumatic brain injury.Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male ratsAdministration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficitsImpact of pharmacological treatments on outcome in adult rodents after traumatic brain injury: a meta-analysis.5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.The Therapeutic Efficacy of Environmental Enrichment and Methylphenidate Alone and in Combination after Controlled Cortical Impact Injury.Impact of Traumatic Brain Injury on Dopaminergic Transmission.Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam.Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
P2860
Q24633449-4ADBAE47-5AB2-4DDF-90C3-262A7CFA8E3BQ24651403-133E2645-7DDC-44A6-B46B-301DA8118453Q28396242-F4C9A5D3-EC8F-43DC-85A3-2FE120FD2201Q28397361-CFC20062-CDD6-4045-B44F-75D378839E89Q28397697-32DBC734-3C68-463A-9188-930BBD6FE7FBQ28397908-6CC13386-6010-489C-BB75-88DBFBFD789AQ33576385-2A949E2F-C2C2-4F61-BC49-771D555CD63AQ33589580-69C850FA-C2B5-4A35-88B0-1887EFAECB97Q34296853-4460BF8D-2FF2-446B-9789-16B3444305B9Q35136513-46D7C1E0-8C77-4B73-BEA8-9F7CB4F703FBQ35894821-3A3D1240-EF36-4B8B-A6F6-10C4E301F54CQ36079887-FDD7E1AA-3CD1-4ACC-88D3-B8E385612A61Q36795887-4F60C356-F609-4DF8-BEB4-554FEE0ED41EQ37018684-293C4C47-86BC-4389-8C72-DD841B6BBE83Q37837257-98AF226C-0147-471F-AB0A-59FDFEFD57BFQ38650071-0C958108-0B42-4ED2-84C1-916BC8BD3366Q39923810-E413C1C3-04E8-4F22-A0B6-8BB6522207A7Q47136786-105FCF48-F3B9-4D5D-B3DB-E1D82334D864Q47371361-5A21772D-028D-4C6B-B720-9BC81D97F1F4Q58739852-B5AED287-9FAC-459A-B7BD-DFF07364A708
P2860
The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@ast
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@en
type
label
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@ast
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@en
prefLabel
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@ast
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@en
P2093
P2860
P1433
P1476
The neurobehavioral benefit co ...... o a narrow therapeutic window.
@en
P2093
Ann N Hoffman
Anthony E Kline
Haris A Aslam
Ross D Zafonte
P2860
P304
P356
10.1016/J.NEULET.2007.02.006
P407
P577
2007-02-07T00:00:00Z